- Home
- CVKD vs BIVI Comparison
CVKD vs BIVI Comparison
Compare CVKD & BIVI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CVKD | BIVI |
|---|---|---|
| Founded | 2022 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medicinal Chemicals and Botanical Products | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.9M | 8.5M |
| IPO Year | 2022 | 2013 |
Fundamental Metrics
Financial Performance| Metric | CVKD | BIVI |
|---|---|---|
| Price | $5.28 | $1.56 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $13.00 | N/A |
| AVG Volume (30 Days) | 48.7K | ★ 53.6K |
| Earning Date | 05-07-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 23.94 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $4.21 | $0.82 |
| 52 Week High | $17.50 | $9.09 |
Technical Indicators
Market Signals| Indicator | CVKD | BIVI |
|---|---|---|
| Relative Strength Index (RSI) | 48.68 | 61.62 |
| Support Level | $5.13 | $1.52 |
| Resistance Level | $8.87 | $1.68 |
| Average True Range (ATR) | 0.49 | 0.08 |
| MACD | 0.14 | 0.02 |
| Stochastic Oscillator | 64.56 | 94.08 |
Price Performance
Historical ComparisonAbout CVKD Cadrenal Therapeutics Inc.
Cadrenal Therapeutics Inc is developing tecarfarin, its drug candidate, for unmet needs in anticoagulation therapy. Tecarfarin is a late-stage novel oral and reversible anticoagulant (blood thinner) designed to prevent heart attacks, strokes, and deaths due to blood clots in patients with rare cardiovascular conditions requiring chronic anticoagulation.
About BIVI BioVie Inc.
BioVie Inc is a clinical-stage company developing drug therapies to treat chronic debilitating conditions including liver disease and neurological and neuro-degenerative disorders and certain cancers. The company is conducting a potentially pivotal Phase 3 randomized, double-blind, placebo-controlled, parallel-group, multicenter study to evaluate NE3107 in patients who have mild to moderate Alzheimer's disease. BIV201 has the potential to improve the health of thousands of patients suffering from life-threatening complications of liver cirrhosis due to hepatitis, non-alcoholic steatohepatitis and alcoholism.